Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.31), $0.03 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $9.59 thousand versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.